e-learning
resources
2021
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Direct oral anticoagulant therapy in patients with morbid obesity after intermediate- or high-risk pulmonary emboli
Daniel J. Lachant, Christina Bach, Alexander Fe, R. James White, Neil A. Lachant
Source:
ERJ Open Res, 7 (1) 00554-2020; 10.1183/23120541.00554-2020
Journal Issue:
January
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Daniel J. Lachant, Christina Bach, Alexander Fe, R. James White, Neil A. Lachant. Direct oral anticoagulant therapy in patients with morbid obesity after intermediate- or high-risk pulmonary emboli. ERJ Open Res, 7 (1) 00554-2020; 10.1183/23120541.00554-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Eosinophils and airway nerves in asthma
Related content which might interest you:
Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018
Direct oral anticoagulant use and thrombus detection in patients with chronic thromboembolic pulmonary hypertension referred for pulmonary thromboendarterectomy
Source: International Congress 2019 – Chronic thromboembolic pulmonary hypertension
Year: 2019
Successful use of sildenafil in the treatment of pulmonary hypertension in patients with severe non-operable chronic thromboembolic disease
Source: Annual Congress 2004 - Treatment of pulmonary hypertension
Year: 2004
Comparison of two regimens of oral anticoagulation in pulmonary embolism
Source: Eur Respir J 2006; 28: Suppl. 50, 632s
Year: 2006
Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism
Source: Eur Respir J 2016; 48: 1360-1368
Year: 2016
Complications of anticoagulant therapy in patients with pulmonary thromboembolism
Source: Eur Respir J 2007; 30: Suppl. 51, 604s
Year: 2007
Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension
Source: Eur Respir Rev 2015; 24: 272-282
Year: 2015
Pulmonary angioplasty vs exclusive medical treatment in inoperable chronic thromboembolic hypertension–initial outcomes from a pulmonary hypertension centre
Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension
Year: 2020
A case-control study on direct oral anticoagulants versus warfarin for acute pulmonary embolism in obese patients
Source: Virtual Congress 2021 – Insights into pulmonary embolism
Year: 2021
Successful pregnancy outcome in patients with pulmonary arterial hypertension receiving prostayclin therapy
Source: Annual Congress 2004 - Pulmonary hypertension
Year: 2004
Pulmonary endarterectomy: the potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension
Source: Eur Respir Rev 2015; 24: 263-271
Year: 2015
Management of anticoagulant and antiplatelet therapy in patients undergoing interventional pulmonary procedures
Source: Eur Respir Rev, 26 (145) 170020; 10.1183/16000617.0020-2017
Year: 2017
Initial dual oral combination therapy prior to pulmonary endarterectomy (PEA) in patients with operable chronic thromboembolic pulmonary hypertension (CTEPH) and high preoperative pulmonary vascular resistance (PVR)
Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension
Year: 2020
Effect of statin therapy in patients with lung cancer on mortality, incidence of infections and pulmonary embolism
Source: Annual Congress 2012 - Screening, diagnosis, staging and treatment strategies for lung cancer
Year: 2012
Frequency of chronic thromboembolic pulmonary hypertension screening after pulmonary embolism in cancer patients.
Source: International Congress 2018 – Pulmonary embolism: long-term sequelae and advances in therapies
Year: 2018
Sequential multimodal therapy in patients with chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension
Year: 2020
Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 272s
Year: 2005
The outcome of anticoagulation alone therapy for patients with submassive pulmonary embolism
Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism
Year: 2019
Perioperative pulmonary complications and management of patients with COPD and esophageal malignancy
Source: Annual Congress 2011 - COPD management
Year: 2011
Direct oral anticoagulants and low-molecular weight heparin for primary prevention of venous thromboembolism in cancer patients: a meta-analysis
Source: Virtual Congress 2020 – From diagnosis to management of pulmonary embolism
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept